KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Capital Expenditures: 2015-2025

Historic Capital Expenditures for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $48.1 million.

  • BeOne Medicines' Capital Expenditures fell 64.02% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.8 million, marking a year-over-year decrease of 56.78%. This contributed to the annual value of $492.7 million for FY2024, which is 12.32% down from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Capital Expenditures is $48.1 million, which was up 19.54% from $40.2 million recorded in Q2 2025.
  • BeOne Medicines' Capital Expenditures' 5-year high stood at $157.9 million during Q3 2023, with a 5-year trough of $32.7 million in Q2 2022.
  • Over the past 3 years, BeOne Medicines' median Capital Expenditures value was $121.5 million (recorded in 2023), while the average stood at $109.4 million.
  • In the last 5 years, BeOne Medicines' Capital Expenditures soared by 271.64% in 2023 and then tumbled by 64.02% in 2025.
  • Over the past 5 years, BeOne Medicines' Capital Expenditures (Quarterly) stood at $115.0 million in 2021, then increased by 5.55% to $121.4 million in 2022, then climbed by 29.34% to $157.0 million in 2023, then crashed by 41.08% to $92.5 million in 2024, then tumbled by 64.02% to $48.1 million in 2025.
  • Its last three reported values are $48.1 million in Q3 2025, $40.2 million for Q2 2025, and $60.0 million during Q1 2025.